Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Clin Sci (Lond). 2011 Nov;121(9):367-87. doi: 10.1042/CS20110164.
The discovery of mammalian TLRs (Toll-like receptors), first identified in 1997 based on their homology with Drosophila Toll, greatly altered our understanding of how the innate immune system recognizes and responds to diverse microbial pathogens. TLRs are evolutionarily conserved type I transmembrane proteins expressed in both immune and non-immune cells, and are typified by N-terminal leucine-rich repeats and a highly conserved C-terminal domain termed the TIR [Toll/interleukin (IL)-1 receptor] domain. Upon stimulation with their cognate ligands, TLR signalling elicits the production of cytokines, enzymes and other inflammatory mediators that can have an impact on several aspects of CNS (central nervous system) homoeostasis and pathology. For example, TLR signalling plays a crucial role in initiating host defence responses during CNS microbial infection. Furthermore, TLRs are targets for many adjuvants which help shape pathogen-specific adaptive immune responses in addition to triggering innate immunity. Our knowledge of TLR expression and function in the CNS has greatly expanded over the last decade, with new data revealing that TLRs also have an impact on non-infectious CNS diseases/injury. In particular, TLRs recognize a number of endogenous molecules liberated from damaged tissues and, as such, influence inflammatory responses during tissue injury and autoimmunity. In addition, recent studies have implicated TLR involvement during neurogenesis, and learning and memory in the absence of any underlying infectious aetiology. Owing to their presence and immune-regulatory role within the brain, TLRs represent an attractive therapeutic target for numerous CNS disorders and infectious diseases. However, it is clear that TLRs can exert either beneficial or detrimental effects in the CNS, which probably depend on the context of tissue homoeostasis or pathology. Therefore any potential therapeutic manipulation of TLRs will require an understanding of the signals governing specific CNS disorders to achieve tailored therapy.
哺乳动物 TLRs(Toll-like receptors)的发现,最初是基于其与果蝇 Toll 的同源性,于 1997 年确定的,这极大地改变了我们对固有免疫系统如何识别和应对各种微生物病原体的理解。TLRs 是进化上保守的 I 型跨膜蛋白,在免疫和非免疫细胞中表达,其特征是 N 端富含亮氨酸重复序列和高度保守的 C 端结构域,称为 TIR [Toll/白细胞介素 (IL)-1 受体] 结构域。TLR 信号在受到其配体刺激后,会引发细胞因子、酶和其他炎症介质的产生,这些物质会对中枢神经系统 (CNS) 内环境稳态和病理学的几个方面产生影响。例如,TLR 信号在中枢神经系统微生物感染期间启动宿主防御反应中起着至关重要的作用。此外,TLRs 是许多佐剂的靶标,这些佐剂不仅能触发固有免疫,还能帮助塑造针对特定病原体的适应性免疫反应。在过去的十年中,我们对 TLR 在中枢神经系统中的表达和功能的了解大大扩展了,新的数据表明 TLR 也对非传染性中枢神经系统疾病/损伤有影响。特别是,TLRs 识别从受损组织中释放的许多内源性分子,并因此影响组织损伤和自身免疫期间的炎症反应。此外,最近的研究表明 TLR 在神经发生、学习和记忆中发挥作用,而没有任何潜在的感染病因。由于它们在大脑中的存在和免疫调节作用,TLRs 成为许多中枢神经系统疾病和传染病的有吸引力的治疗靶点。然而,很明显,TLRs 在中枢神经系统中可能发挥有益或有害的作用,这可能取决于组织内环境稳态或病理学的背景。因此,任何对 TLR 的潜在治疗性操纵都需要了解控制特定中枢神经系统疾病的信号,以实现针对性治疗。